Join us for an exclusive webinar on the German (bio)pharmaceutical market, the fourth largest in the world and a global leader in research, development, and production. Discover the strengths that make Germany a powerhouse in the pharmaceutical industry and explore the opportunities it offers for international companies. This webinar is designed for international companies eager to explore the opportunities within the German (bio)pharma market. Whether you’re looking to export, invest, expand, or stay informed, this session will provide valuable knowledge and actionable insights.
 

 
What You’ll Learn:

• Overview of the German (bio)pharma market
• Insights into Germany’s leading role in R&D and production
• The German reimbursement and pricing system for pharmaceuticals

 
This session is organized by GLOBE – Global Life Sciences Opportunities Business Exchange, an Intellectual Exchange Group with the North Carolina Biotechnology Center. GLOBE partners include the U.S. Commercial Service, Small Business & Technology Development Center, and the Economic Development Partnership of North Carolina.
 
Panelists:
Dr. Marcus Schmidt is Director Chemicals & Healthcare at Germany Trade and Invest (GTAI), the foreign trade and inward investment agency of the Federal Republic of Germany. His industry group advises international healthcare companies expanding into Germany. Dr. Schmidt has been involved with attracting foreign direct investment to Germany since 2000. After working as a Project Manager in Berlin, he served as Director North America in New York and Washington, DC as well as the global Group Director for Technology & Services. In 2023 he was seconded to the Directorate for Innovation and Industry at the Federal Chancellery. Prior to his career in economic development, Dr. Schmidt served in various legal positions in Germany and Japan.
 
Tilo Mandry, Lead International Liaison Manager, IGES Institut, Berlin. Tilo conducts comparative studies on international health systems and reimbursement and pricing procedures for innovative therapies. His focus is on advanced therapies, combinations of drugs and medical devices, digital health applications and orphan drugs. He studied law at the University of Cologne and Vanderbilt University and received his PhD from the Philipps-University of Marburg.